MedTrace Logo

A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.

NCT01704495 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1147

Last updated 2016-03-01

Study results available
· View outcomes & findings →

Summary

The purpose is to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting β2 Agonists (LABA), in Patients with Uncontrolled Persistent Asthma

Conditions

Interventions

DRUG

AZD5069

AZD5069 oral capsules self-administered twice daily.

DRUG

Placebo

Placebo oral capsules self-administered twice daily.

Sponsors & Collaborators

Principal Investigators

  • Bengt Larsson, MEDICAL SCIENCE DIRECTOR · AZ Mondal R&D, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
150 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Bulgaria
  • Canada
  • Czechia
  • Germany
  • Hungary
  • Mexico
  • Poland
  • Romania
  • Russia
  • Slovakia
  • South Africa
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01704495 on ClinicalTrials.gov